drugset
drugset / Trial / NCT01465386

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

NCT01465386 ↗

Phase 2 Terminated 6 enrolled Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well bortezomib works in treating patients with high-risk acute myeloid leukemia (AML) in remission. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Timeline

Start
2011-11
Primary completion
2014-01-28
Completion
2015-03-02

Outcome

Outcome not reported

Stopped (Enrollment): “Closed early due to slow enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Subcutaneous

Indications

acute erythroid leukemia acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with minimal differentiation acute myeloid leukemia with multilineage dysplasia acute promyelocytic leukemia